Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

• Główni autorzy: Adnan Asif Parvez Ghias (Autor), Shahzeem Bhayani (Autor), David J. Gemmel (Autor), Sudershan K. Garg (Autor)
• Format: Książka
• Wydane: Greater Baltimore Medical Center, 2018-03-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case...